A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY-NIPPON
- Sponsors Sanofi
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 09 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated